Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Scientific Reports|June 22, 2019
High-Resolution Copy Number Patterns From Clinically Relevant FFPE MaterialAnastasia Filia, Alastair Droop, Mark Harland, et al.
Cancer Control : Journal of the Moffitt Cancer Center|August 22, 2022
Healthcare Professional and Patient Perceptions of Changes in Colorectal Cancer Care Delivery During the COVID-19 Pandemic and Impact on Health InequalitiesAthena Ip, Georgia Black, Cecilia Vindrola-Padros, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell CarcinomaAlison C Young, Rachel A Craven, Dena Cohen, et al.
Trials|September 16, 2021
BiCyCLE NMES-neuromuscular electrical stimulation in the perioperative treatment of sarcopenia and myosteatosis in advanced rectal cancer patients: design and methodology of a phase II randomised controlled trialEdward T Pring, Laura E Gould, George Malietzis, et al.
BMJ Open|August 28, 2020
Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II)Silviya Balabanova, Claire Taylor, Graeme Sills, et al.
Lancet (London, England)|April 11, 2021
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trialAnthony Marson, Girvan Burnside, Richard Appleton, et al.
Lancet (London, England)|April 11, 2021
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trialAnthony Marson, Girvan Burnside, Richard Appleton, et al.
Health Technology Assessment (Winchester, England)|December 21, 2021
Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTsAnthony G Marson, Girvan Burnside, Richard Appleton, et al.
Blood|July 17, 2008
The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survivalDerville O'Shea, Ciarán O'Riain, Claire Taylor, et al.
Gut|March 11, 2025
British Society of Gastroenterology practice guidance on the management of acute and chronic gastrointestinal symptoms and complications as a result of treatment for cancerJervoise Andreyev, Richard Adams, Jan Bornschein, et al.
Pageof 12